|
Leiden, The Netherlands, June 20, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a PER.C6® research license agreement with Immuno-Biological Laboratories Co., Ltd (IBL), a Japanese company specialising in the production of antibody-based reagents for life science research.
IBL intends to use PER.C6® to develop a range of recombinant protein products that can be used as laboratory reagents. IBL has also obtained an option to a commercial license to manufacture the reagents and offer them for sale for laboratory research purposes.
Under the terms of the agreement, IBL will pay a license issuance fee and annual maintenance fees. Further financial details were not disclosed.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosomal vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. Crucell is represented by Asahi Glass Co. in Japan. For more information, please visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).
For further information please contact:
|
Crucell N.V.
Harry Suykerbuyk
Director Investor Relations and Corporate Communications
Tel. +31-(0)71-524 8718
|
For Crucell in the US:
Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733
|
PDF version
| 
